Year: 2021
Type: editorial
Abstract: Sequential combination of immunogenic cell death (ICD)-induced interventions with subsequent immunotherapy has shown efficacy in preclinical models and clinical evaluation. Recently, a clinical trial enrolling small cell lung cancer patients treated with amrubicin together with PD-1 blockade confirmed the notion that ICD sensitizes tumors to immune checkpoint inhibitors.
Source: OncoImmunology
Authors: Guido Kroemer, Oliver Kepp
Institutions: Centre National de la Recherche Scientifique, Karolinska University Hospital, Inserm, Institut Universitaire de France, Chinese Academy of Medical Sciences & Peking Union Medical College, Université Paris Cité, Université Paris-Saclay, Institut Gustave Roussy, Karolinska Institutet, Sorbonne Université, Centre de Recherche des Cordeliers, La Ligue Contre le Cancer, Hôpital Européen Georges-Pompidou, Suzhou Institute of Systems Medicine
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,913
Funders: Association pour la Recherche sur le Cancer, Seerave Foundation, E-Rare, European Commission, Agence Nationale de la Recherche, Fondation Leducq, Institut National de la Santé et de la Recherche Médicale, Fondation pour la Recherche Médicale, Ligue Contre le Cancer, Labex, Centre National de la Recherche Scientifique, Institut Universitaire de France, Institut National Du Cancer, Cancéropôle Ile de France, Institut Gustave-Roussy, Chancellerie des Universités de Paris, European Research Area Network on Cardiovascular Diseases, Horizon 2020 Framework Programme, Institut national des sciences de l'Univers, Labex Immuno-Oncology, National Cancer Institute
OpenAlex ID: W3211098331
